Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Ke Yang et al.|Journal of Hepatology|2020Cited by 10
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIESStuart C. Gordon, Marlyn J. Mayo, Ke Yang et al.|Gastroenterology|2022Cited by 2
686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDYAndreas E. Kremer, Yun‐Jung Choi, Aliya Gulamhusein et al.|Gastroenterology|2020Cited by 1
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studiesStuart C. Gordon, Marlyn J. Mayo, Kehu Yang et al.|Unknown|2021Cited by 0